Attending ASCO 2026?
Don't go in blind. Get our curated networking cheatsheet with party lists & investor maps.
Join 5,000+ Life Science Leaders
Official Registration
Visit Official Website ↗Strategic Context
ASCO Annual Meeting is the world's leading oncology conference, presenting the latest groundbreaking research and clinical trial data across all cancer types. Attendees gain access to thousands of abstracts, expert-led educational sessions, and opportunities to engage with global oncology leaders. It is an essential event for staying current with advances in cancer treatment, diagnostics, and patient care.
Who Attends
Oncologists, Clinical Researchers, HCPs, Cancer Biologists, Pharmacologists, Patient Advocates
Accommodation for ASCO 2026 typically sells out 3–4 months in advance. We recommend booking hotels near the venue immediately after registration opens.
Coverage from ASCO 2026
Biomarkers and Novel Treatments Highlight Prostate Cancer Advances at ASCO
New research presented at ASCO 2025 details advances in prostate cancer, including prognostic biomarkers and precision therapies for advanced disease.
HYRNUO® (Sevabertinib) Shows Efficacy in Advanced Solid Tumours
Sevabertinib, a novel tyrosine kinase inhibitor, demonstrates efficacy in advanced solid tumours, offering a new therapeutic option.
Oncodetect® MRD Test Shows Analytical Validity, Clinical Utility at ASCO
Molecular residual disease (MRD) detection is critical for oncology. The Oncodetect® test demonstrates analytical and clinical evidence.
Fixed-Duration BCL-2 Combo Offers Time Off Treatment in 1L CLL
A novel fixed-duration combination therapy with a BCL-2 inhibitor as backbone provides treatment-free intervals for patients with first-line CLL.
TACE + Camrelizumab/Rivoceranib Improves OS in Unresectable HCC
A phase II trial demonstrates improved overall survival with TACE combined with camrelizumab and rivoceranib for unresectable HCC.
New 2L+ Combination Therapy Shows Efficacy in RRMM Post-PI/IMiD
A novel 2L+ combination therapy demonstrates improved outcomes for adults with relapsed/refractory multiple myeloma (RRMM) after prior proteasome inhibitor (PI) and immunomodulatory agent (IMiD) exposure.
ASCO 2026 June 1st Program Highlights: Novel Immunotherapy Data
The ASCO 2026 June 1st program focused on advancements in immunotherapy, particularly for solid tumours, with new data presented on combination strategies.
Subcutaneous Immunotherapy Offers Alternative Administration at ASCO 2026
A new subcutaneous immunotherapy formulation provides a convenient alternative for patients, potentially reducing administration time and healthcare resource utilization.
MCED Tests Show Promise for Earlier Cancer Detection at ASCO 2026
Multi-cancer early detection (MCED) tests offer a potential strategy for earlier cancer diagnosis, particularly for cancers lacking standard screening.
Doctor-Patient Communication Improves Treatment Acceptance in Cancer
Effective doctor-patient communication, focusing on patient self-blame, significantly increases treatment acceptance rates in cancer patients.
ASCO 2026 May 31st Program Highlights: Focus on Novel Immunotherapies
The ASCO 2026 May 31st program highlighted advancements in novel immunotherapies, particularly in solid tumours and haematological malignancies.
Myriad's Precise MRD™ Test Shows Ultra-Sensitive Detection at ASCO 2026
Myriad's Precise MRD™ test offers ultra-sensitive molecular residual disease detection, potentially guiding adjuvant therapy decisions.
Tafasitamab-R-CHOP Boosts Frontline DLBCL Outcomes at ASCO 2026
New data presented at ASCO 2026 indicate that tafasitamab combined with R-CHOP improves outcomes for newly diagnosed DLBCL patients.
Bispecific Antibodies Efficacious in Multiple Myeloma with Renal Impairment
A systematic review confirms bispecific antibodies show comparable efficacy and manageable safety in relapsed/refractory multiple myeloma patients with renal impairment.
Tile Radiation for Large Brain Mets: A New Approach at ASCO 2026
Tile-based radiation therapy for large brain metastases was presented at ASCO 2026, offering a novel strategy for dose escalation.
More Breast Cancer Patients Can Skip Axillary Dissection
New data presented at ASCO 2026 indicates an expanded cohort of breast cancer patients can safely omit axillary lymph node dissection.
MLVs: Dual Role in Brain Metastases Offers Therapeutic Targets
Meningeal lymphatic vessels (MLVs) exhibit a dual role in brain metastases, initially promoting anti-tumor immunity but later facilitating dissemination.
PEAK Study Shows Novel Agent Improves PFS in Advanced GIST
The Phase 3 PEAK study demonstrated improved progression-free survival with a novel therapeutic agent in advanced gastrointestinal stromal tumors (GIST).
Outsmarting Shape-Shifting Lung Cancer Resistance
Resistance to EGFR inhibitors is almost inevitable — but the mechanisms are predictable and increasingly targetable. From T790M acquired resistance to osimertinib, through FLAURA2 combination strategies, Sarah Mitchell and James Carter explain how the field is staying one step ahead of lung cancer.
TRUQAP + Fulvestrant: 2L Option for HR+/HER2- aBC/mBC with PI3K-AKT Alterations
TRUQAP with fulvestrant offers a second-line treatment for HR+/HER2- advanced or metastatic breast cancer with specific PI3K-AKT pathway alterations.
ICI Dissemination Challenges Highlighted at ASCO 2026
Global disparities in immune checkpoint inhibitor access and toxicity management were a key focus at ASCO 2026, revealing persistent implementation gaps.
ASCO 2026 May 29th Program Highlights: Novel Oncology Therapies
The ASCO 2026 May 29th program focused on advancements in targeted therapies and immunotherapies across various cancer types, presenting data on efficacy and safety.
HER2-Expressing Breast Cancer: Advancements in Targeted Therapies
New therapeutic strategies for HER2-expressing breast cancer presented at ASCO 2026 demonstrate improved outcomes across disease stages.
Inluriyo™ and Verzenio® Presentations at ASCO 2026
Upcoming ASCO 2026 presentations will detail imlunestrant and abemaciclib, offering new data on endocrine therapy for breast cancer.
Immunotherapy and Targeted Therapy: New Data from ASCO 2026
New research from ASCO 2026 explores combination strategies for advanced cancers and a machine learning approach to immunotherapy target discovery.
Symptom Science Integration Improves Cancer Outcomes at ASCO 2026
Translating symptom science into clinical practice demonstrably improves patient outcomes in oncology, as highlighted at ASCO 2026.
Cancer Elimination at ASCO 2026: Aspirational Goals and Current Realities
ASCO 2026 will address cancer elimination, focusing on prevention, early detection, and treatment advancements. Current evidence suggests a multi-faceted approach is necessary.
How Immunotherapy Unmasks Invisible Lung Cancer
PD-L1 expression is the gatekeeper to first-line immunotherapy in NSCLC — but the biology of why some tumours respond and others do not remains one of oncology's central questions. Sarah Mitchell and James Carter examine the landmark trials that established checkpoint inhibitors as standard of care.
Cancer Care Disparities Highlighted in Crisis, Displaced Populations
ASCO 2026 discussions underscore significant challenges in delivering equitable cancer care during crises and to immigrant and displaced populations.
ASCO 2026 May 30th Program Highlights: Immunotherapy Advances in Solid Tumors
The ASCO 2026 May 30th program focused on immunotherapy in solid tumors, presenting data on novel combinations and biomarker-driven strategies.
Radiopharmaceutical Therapy: Improving Effectiveness, Access, and Safety
Radiopharmaceutical therapy (RPT) offers targeted cancer treatment, but challenges in efficacy, patient access, and risk mitigation persist.
AI Foundation Models Enhance Diagnostic Insights in Oncology
AI foundation models presented at ASCO 2026 demonstrate potential to improve diagnostic precision and challenge existing oncology paradigms.
Novel Biomarkers Improve Pediatric Solid Tumor Detection
New biomarkers enhance early detection and risk stratification in pediatric solid tumors, offering potential for more targeted therapeutic strategies.
CELMoDs Show Promise in Relapsed/Refractory Multiple Myeloma
Emerging CELMoD research at ASCO 2026 highlights novel therapeutic strategies for relapsed/refractory multiple myeloma, addressing evolving patient needs.
Yoga Reduces Insomnia, Fatigue, Anxiety in Cancer Survivors
A new study presented at ASCO 2026 demonstrates yoga significantly improves insomnia, fatigue, and anxiety in cancer survivors.
ASCO 2026: Anticipating Advances in Oncology Treatment
ASCO 2026 is expected to highlight progress in targeted therapies, immunotherapy, and precision oncology, with a focus on biomarker-driven treatment strategies.
Few Pediatric Cancer Drugs Reach Phase 3 or Approval
The pipeline for pediatric oncology drugs remains sparse, with most candidates failing to progress beyond early-phase trials to approval.
Early Breast Cancer at ASCO 2026: Trials to Watch
ASCO 2026 is expected to bring pivotal data on adjuvant and neoadjuvant strategies in early breast cancer. Here is what clinicians should watch for.